Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-31
2011-05-31
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S601000
Reexamination Certificate
active
07951831
ABSTRACT:
The invention relates to methods, compositions, and uses of those compositions for making medicaments, for potentiating the beneficial effects of inhibitors of COX-1, COX-2, and 5-LOX, and reducing adverse effects, by also administering inhibitors of soluble epoxide hydrolase (“sEH”), with or without also administering one or more cis-epoxyeicosantrienoic acids. The invention further relates to the use of inhibitors of sEH as analgesics and to methods and compositions of epoxides of eicosapentaenoic acid and docosahexaenoic acid, optionally with an inhibitor of sEH, to reduce pain or inflammation or both.
REFERENCES:
patent: 5962455 (1999-10-01), Blum et al.
patent: 6136839 (2000-10-01), Isakson et al.
patent: 6531506 (2003-03-01), Kroetz et al.
patent: 2005/0026844 (2005-02-01), Hammock et al.
patent: 5 059032 (1993-03-01), None
patent: 99/54282 (1999-10-01), None
patent: 01/10438 (2001-02-01), None
patent: 02/089787 (2002-11-01), None
patent: 2004/089296 (2004-10-01), None
patent: 2005/089380 (2005-09-01), None
Chiang, N., et al., “Aspirin triggers anti-inflammatory 15-epi-lipoxin A4and inhibits thromboxane in a randomized human trial,”PNASvol. 101(42), pp. 15178-15183 (Oct. 19, 2004).
Finley, B., et al., “Increased cholesterol epoxide hydrolase activity in clofibrate-fed animals,”Biochemical Pharmacology, vol. 37(16), pp. 3169-3175 (1988).
Gilroy, D., et al., “COX-2 expression and cell cycle progression in human fibroblasts,”Am. J. Physiol. Cell Physiol., vol. 281, pp. C188-C194 (2001).
Gilroy, D., et al., “Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts,”The FASEB Journal, vol. 15, pp. 288-290 (Feb. 2001).
Karara, A., et al., “Endogenous epoxyeicosatrienoic acids,”The Journal of Biological Chemistry, vol. 264 (33), pp. 19822-19827 (1989).
Meade, E., et al., “Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells,”The Journal of Biological Chemistry, vol. 274(12), pp. 8328-8334 (1999).
Seibert, K., et al., “Role of inducible cyclooxygenase (COX-2—in inflammation,” Receptor, vol. 4, pp. 17-23 (1994).
Serhan, C., et al., “Unorthodox routes to prostandoid formation: new twists in cyclooxygenase-initiated pathways,”The Journal of Clinical Investigation, vol. 107(12), pp. 1481-1489 (Jun. 2001).
Goodman & Gilman's: “The Pharmacological Basis of Therapeutics”; 2001, Tenth Edition, Table 27-3, p. 710.
Office Communication from U.S. Appl. No. 10/694,641, dated Jun. 22, 2010 (7 pages).
Extended Supplementary European Search Report and Written Opinion mailed Sep. 27, 2010, from Application No. 06733676.8.
Hammock Bruce D.
Inceoglu Ahmet Bora
Schmelzer Kara
Claytor Renee
Padmanabhan Sreeni
The Regents of the University of California
Weaver Austin Villeneuve & Sampson LLP
LandOfFree
Use of inhibitors of soluble epoxide hydrolase to synergize... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of inhibitors of soluble epoxide hydrolase to synergize..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of soluble epoxide hydrolase to synergize... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2634941